Although we cannot exclude that increased frequencies of Ki67+PD-1+CD8 T cells depend on tumor type, mutational load and/or certain patient subgroups, our findings do argue that further studies are required to better define how the Ki67 marker relates to clinical response to checkpoint inhibition. The gene discussed is MKI67; the disease is neoplasm.